CN111050803A - 用于治疗癌症的干扰素前药 - Google Patents
用于治疗癌症的干扰素前药 Download PDFInfo
- Publication number
- CN111050803A CN111050803A CN201880053451.8A CN201880053451A CN111050803A CN 111050803 A CN111050803 A CN 111050803A CN 201880053451 A CN201880053451 A CN 201880053451A CN 111050803 A CN111050803 A CN 111050803A
- Authority
- CN
- China
- Prior art keywords
- ifn
- cancer
- pat
- interferon
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762522564P | 2017-06-20 | 2017-06-20 | |
| US62/522,564 | 2017-06-20 | ||
| PCT/US2018/037982 WO2018236701A1 (en) | 2017-06-20 | 2018-06-18 | INTERFERON PRODRUCE FOR THE TREATMENT OF CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111050803A true CN111050803A (zh) | 2020-04-21 |
Family
ID=64737368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880053451.8A Pending CN111050803A (zh) | 2017-06-20 | 2018-06-18 | 用于治疗癌症的干扰素前药 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200123227A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3641829A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2020528878A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20200015742A (cg-RX-API-DMAC10.html) |
| CN (1) | CN111050803A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3067539A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018236701A1 (cg-RX-API-DMAC10.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025201363A1 (zh) * | 2024-03-27 | 2025-10-02 | 高雄医学大学 | 细胞因子阻断抗体及其应用 |
| WO2026158523A1 (en) * | 2025-01-24 | 2026-07-30 | Tj Biopharma (Hangzhou) Co., Ltd. | Masked multifunctional proteins |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CA3136602A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| BR112021022666A2 (pt) | 2019-05-14 | 2022-03-29 | Werewolf Therapeutics Inc | Frações de separação e seus métodos e uso |
| CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| AU2020316002B2 (en) * | 2019-07-25 | 2026-05-07 | The University Of Chicago | Compositions and methods comprising protease-activated therapeutic agents |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| AU2021205981A1 (en) | 2020-01-11 | 2022-07-14 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| US20240076355A1 (en) * | 2021-01-14 | 2024-03-07 | AskGene Pharma, Inc. | Interferon Prodrugs and Methods of Making and Using the Same |
| KR20230157448A (ko) * | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| KR20240021943A (ko) * | 2021-06-18 | 2024-02-19 | 남미 테라퓨틱스, 인크. | 암의 치료에 사용하기 위한 마스킹된 유형 I 인터페론 (IFNα 및 IFNβ)을 포함하는 융합 단백질 조성물(들) 및 그의 방법 |
| EP4387987A2 (en) * | 2021-08-18 | 2024-06-26 | Werewolf Therapeutics, Inc. | Activatable inteferon polypeptides and methods of use thereof |
| US20240400633A1 (en) * | 2021-09-30 | 2024-12-05 | Orionis Biosciences, Inc. | Split human ifn-gamma and tnf-alpha constructs and uses thereof |
| WO2023060156A2 (en) * | 2021-10-08 | 2023-04-13 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| MX2024004301A (es) * | 2021-10-08 | 2024-04-26 | Cytomx Therapeutics Inc | Construcciones de citocinas activables y metodos combinados. |
| US20240067691A1 (en) * | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| WO2024186193A1 (ko) * | 2023-03-08 | 2024-09-12 | 인제대학교 산학협력단 | 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물 |
| KR20260026098A (ko) * | 2023-05-12 | 2026-02-25 | 리제너론 파아마슈티컬스, 인크. | 인터페론 수용체 길항제 및 이의 용도 |
| EP4750813A1 (en) * | 2023-07-25 | 2026-06-03 | TJ Biopharma (Shanghai) Co., Ltd. | Masked interferon fusion proteins and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014652A1 (en) * | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| WO2009025846A2 (en) * | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| WO2010096838A2 (en) * | 2009-02-23 | 2010-08-26 | Cytomx Therapeutics, Llc | Proproteins and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL197568B1 (pl) * | 1997-12-19 | 2008-04-30 | Applied Research Systems | Kompleks zawierający IFN typu I oraz podjednostkę IFNAR, jego zastosowanie, cząsteczka DNA i wektor ją zawierający, komórka gospodarza transformowana wektorem, kompozycja farmaceutyczna, lek, zastosowanie IFNAR, zastosowanie IFN typu I i podjednostki IFNAR, sposób wytwarzania białka fuzyjnego oraz sposób przedłużania okresu trwałości IFN |
| US20100189727A1 (en) * | 2008-12-08 | 2010-07-29 | Tegopharm Corporation | Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
-
2018
- 2018-06-18 JP JP2019570445A patent/JP2020528878A/ja active Pending
- 2018-06-18 EP EP18820121.4A patent/EP3641829A4/en not_active Withdrawn
- 2018-06-18 CN CN201880053451.8A patent/CN111050803A/zh active Pending
- 2018-06-18 WO PCT/US2018/037982 patent/WO2018236701A1/en not_active Ceased
- 2018-06-18 CA CA3067539A patent/CA3067539A1/en active Pending
- 2018-06-18 US US16/624,648 patent/US20200123227A1/en not_active Abandoned
- 2018-06-18 KR KR1020207000744A patent/KR20200015742A/ko not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014652A1 (en) * | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| WO2009025846A2 (en) * | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| WO2010096838A2 (en) * | 2009-02-23 | 2010-08-26 | Cytomx Therapeutics, Llc | Proproteins and methods of use thereof |
Non-Patent Citations (1)
| Title |
|---|
| LIDA RADFAR,ET AL.: "Biological therapy and dentistry: a review paper", 《ORAL SURGERY,ORAL MEDICINE,ORAL PATHOLOGY AND ORAL RADIOLOGY》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025201363A1 (zh) * | 2024-03-27 | 2025-10-02 | 高雄医学大学 | 细胞因子阻断抗体及其应用 |
| WO2026158523A1 (en) * | 2025-01-24 | 2026-07-30 | Tj Biopharma (Hangzhou) Co., Ltd. | Masked multifunctional proteins |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3067539A1 (en) | 2018-12-27 |
| RU2020101640A (ru) | 2021-07-20 |
| RU2020101640A3 (cg-RX-API-DMAC10.html) | 2021-09-23 |
| EP3641829A1 (en) | 2020-04-29 |
| JP2020528878A (ja) | 2020-10-01 |
| US20200123227A1 (en) | 2020-04-23 |
| EP3641829A4 (en) | 2021-04-21 |
| KR20200015742A (ko) | 2020-02-12 |
| WO2018236701A1 (en) | 2018-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200123227A1 (en) | Interferon prodrug for the treatment of cancer | |
| US11873486B2 (en) | Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon | |
| ES2547568T3 (es) | Polimorfismos de VEGF y terapia anti-angiogénesis | |
| US8278061B2 (en) | Polymorphisms in the EGFR pathway as markers for cancer treatment | |
| EA013617B1 (ru) | Мутации рецептора эпидермального фактора роста | |
| US20060115827A1 (en) | Genetic markers for predicting disease and treatment outcome | |
| CA2952181A1 (en) | Activating jak kinase biomarkers predictive of anti-immune checkpoint inhibitor response | |
| CA2835179A1 (en) | Markers for cancer prognosis and therapy and methods of use | |
| US20120094291A1 (en) | FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME | |
| US20050053958A1 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
| US11852631B2 (en) | Biomarkers predictive of anti-immune checkpoint response | |
| KR20160003141A (ko) | 암을 치료하는 방법 | |
| JP2015502137A (ja) | E1酵素変異体およびその用途 | |
| CN102498219A (zh) | 在得自对象的生物学样品中评价癌症的方法 | |
| US20050064442A1 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
| RU2788736C2 (ru) | Пролекарство интерферона для лечения рака | |
| CA3116698A1 (en) | Identification and targeting of pathogenic extracellular matrix for diagnosis and treatment of cancer and other diseases | |
| US20180052169A1 (en) | Tsp1 as a marker for cancer | |
| CA2845381A1 (en) | Responsiveness to angiogenesis inhibitors | |
| US20040138161A1 (en) | Methods of modulating proliferative conditions | |
| EP2751280B1 (en) | Method for predicting risk of hypertension associated with anti-angiogenesis therapy | |
| HK1243138A1 (en) | Therapeutic and diagnostic methods for il-33-mediated disorders | |
| JPS6163699A (ja) | ヒト形質転換発育因子 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200421 |